Ribavirin

erythropoietin ; Homo sapiens







45 Article(s)
Download
PMID
Title
Pub. Year
#Total Relationships
1 32129203 Ribavirin as a beneficial treatment option for hepatitis C virusassociated glomerular disease. 2020 Jan-Feb 1
2 27760839 Sofosbuvir-based antiviral therapy in hepatitis C virus patients with severe renal failure. 2017 Dec 1 1
3 29270489 Hemodialysis Patients Treated for Hepatitis C Using a Sofosbuvir-based Regimen. 2017 Sep 1
4 23957840 Administration of low-dose epoetin-alpha facilitates adherence to ribavirin in triple therapy with pegylated interferon-alpha-2b and telaprevir. 2014 Oct 4
5 24119110 Adjuvant epoetin-β with peginterferon-α and ribavirin in Japanese ribavirin-intolerant relapsed patients with chronic hepatitis C genotype 2. 2014 Oct 4
6 25227310 Erythropoietin rs1617640 G allele associates with an attenuated rise of serum erythropoietin and a marked decline of hemoglobin in hepatitis C patients undergoing antiviral therapy. 2014 Sep 17 2
7 23386076 Anemia management in patients with chronic viral hepatitis C. 2013 Feb 1
8 23583759 Erythropoietin administration suppresses human monocyte function in vitro and during therapy-induced anemia in HCV patients. 2013 Jun 1
9 23867320 Management of anemia induced by triple therapy in patients with chronic hepatitis C: challenges, opportunities and recommendations. 2013 Dec 1
10 23924660 Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection--a randomized trial. 2013 Nov 1
11 22239497 Critical review of the use of erythropoietin in the treatment of anaemia during therapy for chronic hepatitis C. 2012 Feb 5
12 22239498 Impact of erythropoietin on sustained virological response to peginterferon and ribavirin therapy for HCV infection: a systematic review and meta-analysis. 2012 Feb 1
13 21304937 Ribavirin-induced anemia in hepatitis C virus patients undergoing combination therapy. 2011 Feb 3 1
14 20377423 Preemptive erythropoietin plus high ribavirin doses to increase rapid virological responses in HIV patients treated for chronic hepatitis C. 2010 Apr 1
15 20729740 Suboptimal endogenous erythropoietin response in chronic hepatitis C patients during ribavirin and PEG interferon treatment. 2010 Nov 1
16 19830190 Rituximab therapy for pure red cell aplasia due to anti-epoetin antibodies in a woman treated with epoetin-alfa: a case report. 2009 Jul 6 2
17 20001276 Treatment of hepatitis C virus infection: updated Swedish Consensus recommendations. 2009 1
18 20446436 Anemia--a complication of antiviral treatment in chronic viral hepatitis C. 2009 1
19 17299014 Use of hematopoietic growth factors as adjuvant therapy for anemia and neutropenia in the treatment of hepatitis C. 2007 Feb 1
20 17397412 Strategies for managing anemia in hepatitis C patients undergoing antiviral therapy. 2007 Apr 1
21 17559739 The cost of treating ribavirin-induced anemia in hepatitis C: the impact of using recombinant human erythropoietin. 2007 Jun 4
22 18265628 High dose of erythropoietin in management of interferon/ribavirin induced anemia. 2007 Dec 3
23 16565651 [Complementary treatments of chronic viral hepatitis C]. 2006 Feb 1
24 16629641 Definition and management of anemia in patients infected with hepatitis C virus. 2006 May 1
25 16637862 Pegylated interferon and ribavirin treatment for hepatitis C in haemodialysis patients. 2006 May 1
26 16858501 Clinical recommendations for the use of recombinant human erythropoietin in patients with hepatitis C virus being treated with ribavirin. 2006 Jul 2
27 16980747 Ifn/Rbv treatment induced anemia and its correction with epoetin alpha in patients with hepatitis C. 2006 Aug 1
28 17032193 Erythropoietin treatment is associated with more severe thrombocytopenia in patients with chronic hepatitis C undergoing antiviral therapy. 2006 Oct 1
29 17168855 Ribavirin-induced anemia: mechanisms, risk factors and related targets for future research. 2006 1
30 15597026 The use of growth factors to manage the hematologic side effects of PEG-interferon alfa and ribavirin. 2005 Jan 1
31 15865084 Ribavirin in the treatment of hepatitis C. 2005 Mar-Apr 1
32 15927905 Epoetin alfa for the treatment of combination therapy-induced hemolytic anemia in patients infected with hepatitis C virus. 2005 Jun 1
33 15929778 Antibody-mediated pure red cell aplasia due to epoetin alfa during antiviral therapy of chronic hepatitis C. 2005 Jun 1
34 15081101 Role of epoetin alfa in maintaining ribavirin dose. 2004 Mar 3
35 15117320 Epoetin alfa treatment for acute anaemia during interferon plus ribavirin combination therapy for chronic hepatitis C. 2004 May 2
36 15131791 Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. 2004 May 4
37 15232364 Subnormal rise of erythropoietin in patients receiving interferon and ribavirin combination therapy for hepatitis C. 2004 Aug 5
38 15565613 Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy. 2004 Dec 2
39 16265040 Can epoetin alfa maintain ribavirin doses in patients with hepatitis C virus on combination therapy? 2004 Nov 1
40 12713065 Normal erythropoietin response in chronic hepatitis C patients with ribavirin-induced anaemia. 2003 Feb 8
41 14568602 [Use of erythropoietin in the treatment of anemia induced by ribavirin/interferon in patients with hepatitis C]. 2003 Oct 3
42 14582000 Anemia in the treatment of hepatitis C virus infection. 2003 4
43 14638354 Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa. 2003 Nov 9
44 12001034 Treatment of hepatitis C and anemia in human immunodeficiency virus-infected patients. 2002 May 15 2
45 11569724 A preliminary study of erythropoietin for anemia associated with ribavirin and interferon-alpha. 2001 Sep 1